Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANGION BIOMEDICA CORP.

(ANGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Angion to Participate in Upcoming Investment Conference

11/02/2021 | 12:30am EST

UNIONDALE, N.Y., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced its management team will participate in a fireside chat with Stifel Managing Director and Senior Analyst Annabel Samimy at the Stifel 2021 Virtual Healthcare Conference.

Details are as follows:

Event: Stifel 2021 Virtual Healthcare Conference
Date: Monday, November 15th
Time: 3:20pm Eastern US Time

A webcast of the fireside chat will be accessible online by visiting the events and presentations page under the investors section of Angion’s website at https://ir.angion.com/events-presentations. The webcast will remain archived on Angion’s website for approximately 30 days.

About Angion
Angion is committed to transforming the treatment paradigm for patients suffering from acute organ injuries and fibrotic diseases for which there are no approved medicines or where existing approved medicines have limitations. Angion’s lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic. An exploratory Phase 2 trial of ANG-3777 for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass surgery is ongoing with data expected in the fourth quarter of 2021. Angion is scheduled to begin a Phase 2 trial evaluating ANG-3070, an oral tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in patients with primary proteinuric kidney diseases. Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor. For more information, please visit www.angion.com.

Contact
Daniel Ferry
LifeSci Advisors
617-430-7576
daniel@lifesciadvisors.com


Primary Logo

Source: Angion Biomedica Corp.

2021 GlobeNewswire, Inc., source Press Releases

All news about ANGION BIOMEDICA CORP.
01/05ANGION BIOMEDICA : Current Corporate Presentation
PU
01/05ANGION BIOMEDICA : Results of Operations and Financial Condition - Form 8-K
PU
01/04ANGION BIOMEDICA CORP. : Results of Operations and Financial Condition, Costs Associated w..
AQ
01/04Angion Provides Corporate Update and Announces Participation in Upcoming Investor Confe..
AQ
01/04Angion Biomedica Corp. Provides ANG-3070 Program Update
CI
2021Health Care Stocks Holding Onto Midday Gains
MT
2021Health Care Stocks Flat To Higher Premarket Thursday
MT
2021Angion Biomedica Jumps in Pre-Market Trading After CEO Jay Venkatesan Acquires More Tha..
MT
2021Oppenheimer Adjusts Angion Biomedica PT to $8 From $15, Maintains Outperform Rating
MT
2021Health Care Stocks Mixed Premarket Friday
MT
More news
Analyst Recommendations on ANGION BIOMEDICA CORP.
More recommendations
Financials (USD)
Sales 2021 4,12 M - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 69,5 M 69,5 M -
Capi. / Sales 2021 16,9x
Capi. / Sales 2022 7,16x
Nbr of Employees 72
Free-Float 59,6%
Chart ANGION BIOMEDICA CORP.
Duration : Period :
Angion Biomedica Corp. Technical Analysis Chart | ANGN | US03476J1079 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 2,32 $
Average target price 21,00 $
Spread / Average Target 805%
Managers and Directors
Jay R. Venkatesan President, Chief Executive Officer & Director
Greg S. Curhan Chief Financial Officer
Itzhak D. Goldberg Executive Chairman & Chief Scientific Officer
John F. Neylan Chief Medical Officer & Senior Vice President
Jennifer J. Rhodes Secretary, Chief Compliance Office & Senior VP
Sector and Competitors
1st jan.Capi. (M$)
ANGION BIOMEDICA CORP.-20.00%69
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%53 950
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684